Eckert & Ziegler
Manufacturing · Germany · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Robert-rössle-str. 10, Berlin, Berlin, 1...Phone Number
+49 49309410840Website
www.ezag.comRevenue
$263 MillionStock Symbol
EUZIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Eckert & Ziegler
Eckert & Ziegler Strahlen is one of the world's largest providers of isotope technology for radiation therapy and nuclear medicine. It globally provides nuclear medicine institutions with synthesis technology, quality control instruments, and pharmaceutical grade radioisotopes, among them Yttriga®, a precursor for Yttrium based oncology products, and GalliaPharm®; a Gallium-68 radionuclide generator for diagnostic applications.Explore more
Eckert & Ziegler Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eckert & Ziegler your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Eckert & Ziegler had a recent Job posting/layoffs
Check out if Eckert & Ziegler is spiking on competitors!
Earning: See what the market has to say on Eckert & Ziegler recently announced quarterly report
Product Launch: Get notified when Eckert & Ziegler launches new products
Check if Eckert & Ziegler has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Eckert & Ziegler
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Eckert & Ziegler, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Eckert & Ziegler has new funding data
Recommended Actions
Reach out to Masked Content who joined Eckert & Ziegler as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Eckert & Ziegler is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eckert & Ziegler is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eckert & Ziegler.
Eckert & Ziegler Tech Stack
A closer look at the technologies used by Eckert & Ziegler
See more technologies
Most Recent Scoops
Pain Point
Eckert & Ziegler is navigating complex tariff situations affecting exports between Europe, North America, and China. The company's Gallium generator is currently exempted from tariffs due to its high medical need, while some smaller products face a 15% tariff which is being forwarded to customers in North America.
Pricing, Regulations
Project
Eckert & Ziegler is developing Actinium-225 for the treatment of prostate cancer, with regular production expected to start by the end of the year. The company anticipates that Actinium-225 will become a significant business driver from 2028 onwards, following the completion of ongoing clinical studies.
Product Development, Medical Research
Facilities Relocation / Expansion
Eckert & Ziegler is setting up production sites in China, South America, North America, and Europe. The company is investing approximately $20 million annually in CapEx for these expansions, financed through its generated cash flow.
Facilities Relocation/Expansion, Business Finance, Finance
Earnings
reported that for the fiscal year 2024, revenues were split equally between medical and industrial isotope businesses.
Earnings, Medical Research, Industrial Engineering, Finance
Project
Product Development, Manufacturing Operations
Eckert & Ziegler News & Media
Eckert & Ziegler signs manufacturing deal with Pentixapharm - AuntMinnie
Eckert & Ziegler Radiopharma GmbH has signed a manufacturing agreement with Pentixapharm.Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
BERLIN, Dec. 5, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world's largest providers of isotopes for medical,...Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotron-based systems to produce the alpha-emitting isotope, actinium-225 (225Ac). This provides Telix with both an additional commercial source of 225Ac and access to a platform technology that enables highlEckert & Ziegler: Spin-off of Pentixapharm AG Registered - WebDisclosure
Eckert & Ziegler SE successfully completes the spin-off of Pentixapharm AG, transferring shares to Pentixapharm Holding AG as per the approved resolution at the Annual General Meeting
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eckert & Ziegler
Sign Up For FreeTo access detailed company insights
Eckert & Ziegler Strahlen is one of the world's largest providers of isotope technology for radiation therapy and nuclear medicine. It globally provides nuclear medicine institutions with synthesis technology, quality control instruments, and pharmaceutical grade radioisotopes, among them Yttriga®, a precursor for Yttrium based oncology products, a... Read More
